Cargando…
Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial
BACKGROUND: Antipsychotics are essential in the acute treatment of and maintenance therapy for schizophrenia, but medication adherence and long-term treatment continuity are needed to maximize their effectiveness. Each antipsychotic has various side effects, which may affect adherence. Some patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012564/ https://www.ncbi.nlm.nih.gov/pubmed/36918838 http://dx.doi.org/10.1186/s12888-023-04664-5 |
_version_ | 1784906628679598080 |
---|---|
author | Wada, Shuhei Iwamoto, Kunihiro Okumura, Hiroki Hida, Hirotake Hiraoka, Shuichi Kamei, Aya Mori, Daisuke Yamada, Kiyofumi Ozaki, Norio |
author_facet | Wada, Shuhei Iwamoto, Kunihiro Okumura, Hiroki Hida, Hirotake Hiraoka, Shuichi Kamei, Aya Mori, Daisuke Yamada, Kiyofumi Ozaki, Norio |
author_sort | Wada, Shuhei |
collection | PubMed |
description | BACKGROUND: Antipsychotics are essential in the acute treatment of and maintenance therapy for schizophrenia, but medication adherence and long-term treatment continuity are needed to maximize their effectiveness. Each antipsychotic has various side effects, which may affect adherence. Some patients with schizophrenia are reluctant to take asenapine because of its unique oral-related side effects, such as the bitter taste caused by sublingual administration. Our previous basic research found that D-sorbitol lowered the bitterness parameters of the taste sensors. However, whether D-sorbitol has the same effect in patients remains unclear. Therefore, using a D-sorbitol solution, we aim to evaluate changes in the bitterness of asenapine among patients with schizophrenia. METHODS: In this single-blind, placebo-controlled, crossover trial, we plan to recruit 20 adult patients with schizophrenia spectrum disorder who take sublingual asenapine tablets. The participants will be divided into two groups (n = 10 each). Each group will be given a D-sorbitol or placebo solution on the first day for rinsing before taking the sublingual asenapine tablets. After a 1-day interval, the participants will rinse their mouths again with a different liquid. Questionnaires regarding changes in taste and the willingness to continue asenapine will be conducted before the start of the study and after each rinse. The primary and secondary end points will be a taste evaluation of bitterness, and the willingness to continue asenapine, respectively. Differences in questionnaire scores between the D-sorbitol and placebo solutions will be calculated and analyzed using a McNemar test. DISCUSSION: This study aims to determine the efficacy of D-sorbitol in masking the bitter taste of asenapine. To our knowledge, it is the first intervention study using D-sorbitol for bitter taste of asenapine in patients with schizophrenia. Evidence of the efficacy of D-sorbitol could result in D-sorbitol pretreatment being an easy and inexpensive means of improving adherence to asenapine. TRIAL REGISTRATION: This study was registered in the Japan Registry of Clinical Trials jRCTs041210019, on May 14, 2021. Ethics approval was obtained from the Nagoya University Clinical Research Review Board. |
format | Online Article Text |
id | pubmed-10012564 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-100125642023-03-15 Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial Wada, Shuhei Iwamoto, Kunihiro Okumura, Hiroki Hida, Hirotake Hiraoka, Shuichi Kamei, Aya Mori, Daisuke Yamada, Kiyofumi Ozaki, Norio BMC Psychiatry Study Protocol BACKGROUND: Antipsychotics are essential in the acute treatment of and maintenance therapy for schizophrenia, but medication adherence and long-term treatment continuity are needed to maximize their effectiveness. Each antipsychotic has various side effects, which may affect adherence. Some patients with schizophrenia are reluctant to take asenapine because of its unique oral-related side effects, such as the bitter taste caused by sublingual administration. Our previous basic research found that D-sorbitol lowered the bitterness parameters of the taste sensors. However, whether D-sorbitol has the same effect in patients remains unclear. Therefore, using a D-sorbitol solution, we aim to evaluate changes in the bitterness of asenapine among patients with schizophrenia. METHODS: In this single-blind, placebo-controlled, crossover trial, we plan to recruit 20 adult patients with schizophrenia spectrum disorder who take sublingual asenapine tablets. The participants will be divided into two groups (n = 10 each). Each group will be given a D-sorbitol or placebo solution on the first day for rinsing before taking the sublingual asenapine tablets. After a 1-day interval, the participants will rinse their mouths again with a different liquid. Questionnaires regarding changes in taste and the willingness to continue asenapine will be conducted before the start of the study and after each rinse. The primary and secondary end points will be a taste evaluation of bitterness, and the willingness to continue asenapine, respectively. Differences in questionnaire scores between the D-sorbitol and placebo solutions will be calculated and analyzed using a McNemar test. DISCUSSION: This study aims to determine the efficacy of D-sorbitol in masking the bitter taste of asenapine. To our knowledge, it is the first intervention study using D-sorbitol for bitter taste of asenapine in patients with schizophrenia. Evidence of the efficacy of D-sorbitol could result in D-sorbitol pretreatment being an easy and inexpensive means of improving adherence to asenapine. TRIAL REGISTRATION: This study was registered in the Japan Registry of Clinical Trials jRCTs041210019, on May 14, 2021. Ethics approval was obtained from the Nagoya University Clinical Research Review Board. BioMed Central 2023-03-14 /pmc/articles/PMC10012564/ /pubmed/36918838 http://dx.doi.org/10.1186/s12888-023-04664-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Wada, Shuhei Iwamoto, Kunihiro Okumura, Hiroki Hida, Hirotake Hiraoka, Shuichi Kamei, Aya Mori, Daisuke Yamada, Kiyofumi Ozaki, Norio Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
title | Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
title_full | Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
title_fullStr | Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
title_full_unstemmed | Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
title_short | Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
title_sort | sensory evaluation of the bitterness of asenapine using d-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012564/ https://www.ncbi.nlm.nih.gov/pubmed/36918838 http://dx.doi.org/10.1186/s12888-023-04664-5 |
work_keys_str_mv | AT wadashuhei sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT iwamotokunihiro sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT okumurahiroki sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT hidahirotake sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT hiraokashuichi sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT kameiaya sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT moridaisuke sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT yamadakiyofumi sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial AT ozakinorio sensoryevaluationofthebitternessofasenapineusingdsorbitolpretreatmentsingleblindplacebocontrolledcrossovertrial |